Q-omics provides the consensus-scored RPS20P20 profile across patient tissues and cancer cell-line models. RPS20P20 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS20P20 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, RPS20P20 RNA expression shows 8,943 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, KIRC, and LUAD as cancer lineages where RPS20P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P20 survival associations across molecular data types. RPS20P20 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P20 RNA expression–survival associations across cancer types. High RPS20P20 expression shows unfavorable associations in LIHC, BLCA, KICH, THYM, BRCA and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS20P20 RNA expression.
This table summarizes RPS20P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P20 shows higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher RPS20P20 RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p = .001).
This table shows molecular features associated with RPS20P20 in patient tissues and cancer cell lines. In patient samples, RPS20P20 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
